Skip to main content

Table 2 Cox Regression adjusted for additional markers

From: Long-term follow-up of cytogenetically normal CEBPA-mutated AML

  OS RFS
  HR 95% CI p HR 95% CI p
biCEBPA versus moCEBPA (univariable analysis) 0.4 0.2-0.8 0.008 0.5 0.2-0.9 0.021
biCEBPA versus moCEBPA (adjusted for FLT3-ITD) 0.4 0.2-0.8 0.006 0.5 0.2-0.9 0.021
biCEBPA versus moCEBPA (adjusted for FLT3-TKD) 0.4 0.2-0.8 0.012 0.4 0.2-0.9 0.018
biCEBPA versus moCEBPA (adjusted for FLT3-ITD and FLT3-TKD) 0.4 0.2-0.8 0.006 0.4 0.2-0.8 0.012
biCEBPA versus moCEBPA (adjusted for FLT3-ITD, NPM1 mutations and interaction NPM1/FLT3-ITD) 0.2 0.1-0.5 <0.001 0.2 0.1-0.6 0.003
biCEBPA versus moCEBPA (adjusted for NPM1 mutations) 0.2 0.1-0.5 <0.001 0.2 0.1-0.6 0.002
biCEBPA versus moCEBPA (adjusted for PINAOS or PINARFS (both without biCEBPA)) 0.2 0.1-0.4 <0.001 0.2 0.1-0.6 0.001
  1. Abbreviations: biCEBPA biallelic mutation in the CCAAT/enhancer-binding protein alpha, CI confidence interval, FLT3-ITD internal tandem duplication of the FLT3 gene, FLT3-TKD mutation in the tyrosine kinase domain of the FLT3 gene, HR hazard ratio, interaction NPM1/FLT3-ITD, NPM1 positive/FLT3-ITD positive versus NPM1 negative or FLT3-ITD negative, moCEBPA monoallelic mutation in the CCAAT/enhancer-binding protein alpha, NPM1, nucleophosmin gene, OS Overall survival, p p value, PINA OS Prognostic Index for OS in cytogenetically normal AML [29], PINA RFS Prognostic Index for RFS in cytogenetically normal AML [29], RFS Relapse-free survival.